LTRN vs. CLNN, RPHM, BLRX, EGRX, HCWB, EQ, IMMX, CELU, ELDN, and JAGX
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Clene (CLNN), Reneo Pharmaceuticals (RPHM), BioLineRx (BLRX), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Equillium (EQ), Immix Biopharma (IMMX), Celularity (CELU), Eledon Pharmaceuticals (ELDN), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
23.3% of Clene shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 25.1% of Clene shares are held by company insiders. Comparatively, 6.9% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Clene had 11 more articles in the media than Lantern Pharma. MarketBeat recorded 16 mentions for Clene and 5 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.34 beat Clene's score of -0.41 indicating that Clene is being referred to more favorably in the media.
Lantern Pharma has lower revenue, but higher earnings than Clene. Lantern Pharma is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Lantern Pharma has a net margin of 0.00% compared to Lantern Pharma's net margin of -7,873.23%. Clene's return on equity of -39.09% beat Lantern Pharma's return on equity.
Clene currently has a consensus price target of $6.50, indicating a potential upside of 1,581.76%. Given Lantern Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Clene is more favorable than Lantern Pharma.
Clene has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
Clene received 46 more outperform votes than Lantern Pharma when rated by MarketBeat users. Likewise, 75.32% of users gave Clene an outperform vote while only 75.00% of users gave Lantern Pharma an outperform vote.
Summary
Clene beats Lantern Pharma on 11 of the 17 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
